FYI on MRI: decision support to help high-risk Black and Latina women decide about screening breast MRI
Official title: The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI
Run by Georgetown University · NCT06892275 · Data updated 2026-11-12
This project will test whether adding a decision aid to risk assessment and nurse referral helps high-risk Black and Latina women make informed choices about screening breast MRI.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 74 Years |
| Sex | Women only |
| Enrollment | 80 (estimated) |
| Sponsor | Georgetown University Academic / other |
| Locations | 1 site (Washington D.C., District of Columbia) |
| Status | Recruiting |
| Started | June 1, 2025 |
| Main results expected | June 2027 |
| Study ends | December 2027 |
| Registry record updated | September 30, 2025 |
| Trial ID | NCT06892275 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Black or Latina women aged 18–74 without a personal history of breast cancer, English- or Spanish-speaking, with a normal mammogram within 12 months and ≥20% lifetime breast cancer risk per the NCI BCRAT are ideal candidates.
✕Probably not a fit
Women who are pregnant, outside the 18–74 age range, have a prior breast cancer diagnosis, or have less than a 20% lifetime risk are unlikely to receive benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized controlled trial will enroll 80 Black and Latina women at high lifetime risk (≥20%) for breast cancer and randomize them to enhanced usual care (risk assessment plus nurse practitioner referral) or decision support (enhanced usual care plus a decision aid). Assessments occur at baseline and one month after the intervention, with the primary outcome defined as an informed decision about breast MRI—sufficient knowledge aligned with personal preferences. The intervention is delivered through a community-based clinic affiliated with Georgetown Lombardi's Ralph Lauren Center, and materials are available in English and Spanish. The trial follows established behavioral intervention design and reporting standards to protect participants and measure outcomes rigorously.
Why it matters
Potential benefit: If successful, this approach could increase the number of high-risk Black and Latina women who choose screening MRI based on clear information and their own preferences.
How similar studies have gone: Decision aids have improved informed decision-making in other screening contexts, but multilevel decision support specifically for screening breast MRI in high-risk Black and Latina women is relatively untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * female * aged 18-74 years * self-identifying as Black and/or Latina * no personal history of breast cancer * English- or Spanish-speaking * having received a mammogram with normal results in the last 12 months * ≥20% lifetime breast cancer risk per the NCI Breast Cancer Risk Assessment Tool (BCRAT) Exclusion Criteria: * aged \<18 or ≥75 * pregnancy
Where it's running
-
Georgetown University
Washington D.C., District of Columbia, United States Recruiting
Study contacts
- Principal investigator: Claire C. Conley, PhD — Georgetown University
- Study coordinator: Claire C. Conley, PhD
- Email: claire.conley@georgetown.edu
- Phone: 2026875086
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Methylation markers in self-samples to help detect gynecological cancers
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.
-
Pre-Treatment Breast DCE-MRI AI Model to Predict Benefit from Neoadjuvant Chemo in Locally Advanced Triple-Negative Breast Cancer
This study tests an AI model using pre-treatment breast MRI to see if it can identify which locally advanced triple-negative breast cancer patients will benefit most from neoadjuvant chemotherapy.
-
Methylscape test in body fluids for multi-cancer detection in Colombia
A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.
-
Empowering patients to get lung cancer screening with support and navigation
This pilot study tests a patient navigation and education program to see if it helps adults who are eligible start and complete low-dose CT lung cancer screening.
-
Breast ultrasound screening for older women in community clinics
This study tests whether offering breast ultrasound to women aged 65–80 in local communities helps find breast cancers earlier than usual care.
-
Text reminders to boost colorectal cancer screening participation
A large group of people aged 50–69 in Vallès Occidental will be randomised to receive a reminder text message five weeks after an initial invitation, to see if it increases uptake of the FIT screening compared with the standard postal letter.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.